[{"address1": "16 Abba Hillel Road", "city": "Ramat Gan", "zip": "5250608", "country": "Israel", "phone": "972 3 693 8448", "website": "https://www.galmedpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Mr. Allen  Baharaff", "age": 58, "title": "Co-Founder, President, CEO & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 972158, "exercisedValue": 0, "unexercisedValue": 1834}, {"maxAge": 1, "name": "Mr. Doron  Cohen", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 245982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Nehemya", "age": 38, "title": "COO & Data Protection Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 287036, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yohai  Stenzler CPA", "age": 40, "title": "Chief Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 290568, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tali  Gorfine", "age": 53, "title": "Medical Consultant", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 202763, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.81, "open": 4.79, "dayLow": 4.1989, "dayHigh": 4.79, "regularMarketPreviousClose": 4.81, "regularMarketOpen": 4.79, "regularMarketDayLow": 4.1989, "regularMarketDayHigh": 4.79, "beta": 0.73, "forwardPE": -4.4077673, "volume": 121299, "regularMarketVolume": 121299, "averageVolume": 2635271, "averageVolume10days": 198590, "averageDailyVolume10Day": 198590, "marketCap": 6841734, "fiftyTwoWeekLow": 2.73, "fiftyTwoWeekHigh": 23.8, "fiftyDayAverage": 4.79316, "twoHundredDayAverage": 4.38207, "currency": "USD", "enterpriseValue": -7417276, "floatShares": 513945, "sharesOutstanding": 1506990, "sharesShort": 34164, "sharesShortPriorMonth": 40640, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0227, "heldPercentInsiders": 0.01286, "heldPercentInstitutions": 0.02308, "shortPercentOfFloat": 0.023, "bookValue": 22.244, "priceToBook": 0.20409998, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -5883000, "trailingEps": -10.44, "forwardEps": -1.03, "enterpriseToEbitda": 1.207, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GLMD", "underlyingSymbol": "GLMD", "shortName": "Galmed Pharmaceuticals Ltd.", "longName": "Galmed Pharmaceuticals Ltd.", "firstTradeDateEpochUtc": 1394717400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ade4d27e-0850-308a-ae7b-98b5c772bca9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.54, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 9823000, "totalCashPerShare": 18.538, "ebitda": -6145000, "quickRatio": 6.408, "currentRatio": 6.484, "returnOnAssets": -0.29313, "returnOnEquity": -0.52666, "freeCashflow": -4066250, "operatingCashflow": -5922000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]